Jefferies Downgrades Discovery Lab (DSCO) Two-Notches To Underperform
More News related to DSCO
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
- Discovery Labs' Third Quarter 2009 Financial Update
- Discovery Labs Provides Business and Pipeline Development Update
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
More News related to Downgrades
- TransDigm (TDG) Continues Lower as Davenport Downgrades Intraday
- Jefferies & Co Downgrades Cardinal Health (CAH) to Hold
- William Blair Downgrades CVS Caremark (CVS) to Market Perform
- ThinkEquity Downgrades Move, Inc. (MOVE) to Hold
- Morgan Stanley Downgrades ResMed (RMD) to Equalweight
Jefferies downgrades Discovery Lab (Nasdaq: DSCO) from Buy to Underperform.
Shares of DSCO sank 52% on Friday after saying the FDA will now apply a newly-defined standard to determine whether Discovery Labs has adequately demonstrated comparability of Surfaxin clinical to commercial drug product.
Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases.
Related Categories
DowngradesStocks Mentioned
+0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
